Craniopharyngiomas are primary brain tumors of the sellar region that are presumed to arise from embryologic remnants of Rathke's pouch. 1, 2 Although craniopharyngiomas have a benign histology and the 10-year survival rate is higher than 90%, quality of life is frequently impaired by the involvement of neurohormonal structures, including the optic nerves, the pituitary gland, and the hypothalamus. 3, 4 Complete surgical resection is attempted when possible, but partial resection is favored to preserve function when the tumor involves the hypothalamus. Radiation therapy is commonly used to manage residual tumor and recurrence. 5 Currently, US Food and Drug Administration-approved systemic treatments are not available for patients in whom craniopharyngiomas recur after surgery and radiation.
Craniopharyngiomas are divided into 2 main subtypes-adamantinomatous craniopharyngiomas and papillary craniopharyngiomas (PCPs)-that exhibit different clinical and molecular features (Table 1) . 6, 7 A hallmark of PCPs is their supradiaphragmatic location. Surgical resection is challenging because of the proximity to critical structures and is typically performed via a traditional transcranial approach or an endoscopic endonasal approach. 8 The extent of resection varies with the tumor size and location. Despite the benign nature of these tumors, recurrences are common and necessitate further surgery or radiation. Consequently, morbidity due to neurological and endocrinological complications is high, with potentially devastating effects, including visual loss and hypothalamic dysfunction. 9, 10 
BRAF Inhibitors in PCPs
Five years ago, we reported that nearly all PCPs have BRAF V600E (BRAF V600E ) mutations, which constitutively activate the mitogen-activated protein kinase signaling pathway. 7 BRAF V600E mutations are recurrent aberrations in neoplasms such as melanoma that can demonstrate remarkable sensitivity to BRAF inhibitors. 11 Similarly, our group and others have published case reports of dramatic responses in patients with BRAF V600E -mutant PCP treated with BRAF and/or mitogen-activated protein kinase kinase (MEK) inhibitors.
In this article, authors from all 5 previously published reports share their collective experience, provide updated follow-up on their patients, and thus generate an overview of all currently available information on targeted therapy in patients with BRAF V600E -mutant PCP ( Table 2 ). [12] [13] [14] [15] [16] We have also included information on an additional patient with PCP recently treated at Massachusetts General Hospital (patient PCP6). He was 21 years old when he presented with several months of intermittent headaches and progressive fatigue. He also reported difficulty in concentrating, weight gain, and nausea. An ophthalmologic evaluation identified visual field deficits, and brain magnetic resonance imaging (MRI) revealed an enhancing suprasellar mass. He underwent biopsy of the lesion, with pathology demonstrating BRAF V600Emutant PCP. The surgery was complicated by infarcts involving the right anterior choroidal artery territory as well as panhypopituitarism. One month after the operation, imaging revealed continued tumor growth. He was admitted to our institution and was started on dabrafenib and trametinib. Serial MRI scans over the course of 6 months demonstrated a significant reduction in the tumor size with corresponding improvements in his mental status and headaches ( Fig. 1 ). This is the first example of successful neoadjuvant treatment in a patient with BRAF V600E -mutant PCP. At the time of treatment, the tumors in patients PCP1 to PCP5 had recurred after they had undergone surgical resection(s) and/or radiation therapy, whereas treatment in PCP6 was performed after biopsy alone and without any other therapy; this highlights the potential of neoadjuvant treatment. Four patients (PCP1, PCP3, PCP4, and PCP6) received both BRAF and MEK inhibitors, whereas 2 patients (PCP2 and PCP5) received BRAF inhibitor monotherapy (vemurafenib or dabrafenib). Despite different treatment strategies, in all cases, complete or nearly complete tumor regression was achieved, mostly within just a few months after the start of treatment. Both solid and cystic components were responsive. The treatment was well tolerated in most cases, but therapy was temporarily held for 1 patient who developed a cerebrospinal fluid (CSF) leak (PCP2) and for another patient who developed pyrexia (PCP3).
In the patient who developed a CSF leak and meningitis (PCP2) while on vemurafenib monotherapy, the tumor had responded to therapy with a nearly complete response and regrew 3 months after treatment was discontinued because of the complications. Tumor control was again achieved with vemurafenib monotherapy but lasted only 7 months, after which the tumor progressed. A significant reduction in the performance status occurred after the CSF leak, so further active treatment was considered inappropriate, and she died 6 months after treatment was discontinued. In 1 patient (PCP1), a dramatic response was achieved after only 1 month of BRAF/MEK inhibitor dual therapy, after which the remaining tumor was resected, and the area was treated with radiation. The patient was well 12 months later and was subsequently lost to follow-up. Similarly, a substantial treatment response was achieved in another patient (PCP4) with BRAF/MEK inhibitor dual therapy, and the residual tumor was treated with radiation. This patient was tumor-free and remained on dual therapy with dabrafenib and trametinib at the time of this writing. In 1 case (PCP5), minimal tumor remained after 9 months of targeted monotherapy with dabrafenib, at which point treatment was discontinued. With the patient off therapy, the tumor had not recurred 18 months later. The dramatic responses achieved in these cases highlight the transformative potential of BRAF -targeted therapy for patients with PCP. The most recently treated patient (PCP6) had a rapid response in the form of an approximately 80% to 90% reduction of the solid and cystic portions within 6 months.
Although these 6 cases are highly informative for guiding patient treatment, uncertainty remains concerning the optimal timing, the particular agents (single-agent or dual therapy) to be used, and the duration of treatment. A combination of dabrafenib and trametinib has been used most frequently (4 of 6 patients); however, more data are needed to decide on the optimal drug combination. The ongoing multicenter phase 2 Alliance A071601 trial (NCT03224767) of vemurafenib and cobimetinib for patients with biopsy-proven residual or recurrent PCP should provide additional information to help to inform patient management.
In addition, the remarkable responses in patients PCP1 to PCP5 with recurrent disease and in PCP6 with neoadjuvant treatment after biopsy signal the potential for using targeted therapy before any surgery. Algorithms for discriminating PCPs from adamantinomatous craniopharyngiomas have been proposed on the basis of retrospective analyses of MRI data. [17] [18] [19] Such approaches will require further refinement and testing in prospective studies. Further diagnostic approaches, including the detection of BRAF mutations in serum, may contribute to preoperative diagnostic evaluations. Circulating BRAF in the blood of a patient with a PCP (PCP2) was previously reported. 12 This liquid biopsy approach would allow not only the noninvasive detection of BRAF mutations but also monitoring of treatment responses. However, until such noninvasive techniques can be demonstrated to be reliable, the diagnosis of a papillary subtype of craniopharyngioma will be made through biopsy, histology review, and molecular assessment. A feasible strategy may be conservative biopsy of a craniopharyngioma that has radiological features suggestive of the papillary subtype with the potential for targeted therapy. In the future, if achievable with high sensitivity and specificity, the noninvasive or minimally invasive diagnosis of PCP would lead to neoadjuvant targeted therapeutic approaches that could further reduce the significant lifelong morbidity associated with these challenging neoplasms beyond what has already been achieved for patients with recurrent disease.
Summary
PCPs are characterized by the presence of BRAF V600E mutations, which are emerging as a useful guide for diagnosis and treatment decision making. The ongoing multicenter phase 2 Alliance A071601 trial is evaluating the efficacy of BRAF and MEK inhibitors for patients with PCP. With continued successful responses, we propose that BRAF (and MEK) inhibitors be evaluated for the neoadjuvant treatment of patients with PCP. This study was conducted according to the guidelines of the Declaration of Helsinki and has been approved by the local ethics committee of our faculty.
